Prosperity Bancshares, a Texas-based regional bank holding company, will announce its third quarter 2026 earnings before the market opens on October 28, 2026. The company invites investors and the public to join a conference call at 10:30 AM Central Time to hear from its executive management team. Prosperity Bancshares operates 353 banking locations across Texas and Oklahoma and offers a range of financial services including personal banking, digital solutions, mortgage services, and wealth management. The call will also address forward-looking statements about the company's future performance and risks. A replay of the call will be available on the company's website for those unable to attend live.
Prosperity Bancshares' upcoming Q3 2026 earnings call is noted here with Pluang's Financials sector data for context. Of 85 priced Financials-sector US stocks tradable on Pluang, 17 rose and 68 fell today. Notable movers include AVAT at USD 1.82 with a 1-day change of -3.19%, GEMI at USD 5.14 down 2.74%, and BBVA at USD 27.87 down 2.69%. This data is as of Oct 01, 2026 03:02 WIB.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
